Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed.
PURPOSE: This phase II trial is studying the side effects and how well sunitinib works in
treating patients with locally advanced bladder cancer.